The hVIVO PLC (LON: HVO) share price, formerly known as Open Orphan, plunged 6.83% after the results of its first-in-human Phase I clinical study evaluating the safety and immunogenicity of AGS-v PLUS were published in eBioMedicine.
YOUR CAPITAL IS AT RISK. 76% OF RETAIL CFD ACCOUNTS LOSE MONEY.
eBioMedicine is a peer-reviewed open-access biomedical journal that is part of The Lancet Discovery Science. AGS-v PLUS is a vaccine candidate against diseases caused by mosquitoes that targets the mosquito’s saliva instead of the pathogens they carry.
Top Broker Recommendation
- eToro Top stock trading platform with 0% commission – Read our Review
- Tickmill Regulated by the FCA – Read our Review
- Admirals (Admiral Markets) More than 4500 stocks & ETFs available – Read our Review
- Spreadex Spreadex has been around for a long time – Read our Review
- IG Top-tier regulation – Read our Review
YOUR CAPITAL IS AT RISK. 76% OF RETAIL CFD ACCOUNTS LOSE MONEY
hVIVO owns a 49% stake in Imutex Ltd, a joint venture with PepTcell Limited, which owns AGS-v PLUS. The company has applied its experience as a contract research organisation (CRO) in developing a new innovative treatment.
Investors reacted negatively to the positive news, maybe because the results were first announced in November 2021, and many were expecting the company to have made progress on the new drug, but it seems this was not the case.
The AGS-v PLUS vaccine candidate utilises a novel proposed dual action mechanism of preventing human infection while controlling the mosquito population by affecting reproduction. The drug has five synthetic peptides originating from proteins found in mosquito saliva.
The study was conducted at the University of Maryland School of Medicine and sponsored by NIAID-NIH. The results indicated that all the formulations of AGS-v PLUS were well-tolerated, with participants not experiencing any serious adverse events.
In addition, all formulations of AGS-v PLUS generated robust humoral and cellular immune responses in participants. The Montanide ISA-51 formulation was the most immunogenic. The drug can potentially treat all the infections caused by mosquitoes, including the Zika virus, dengue fever, chikungunya, West Nile, malaria, and yellow fever.
Yamin ‘Mo' Khan, hVIVO’s CEO, said: “It is encouraging to see the results from Imutex's first-in-human Phase 1 trial for AGS-v PLUS published in eBioMedicine. The data demonstrated that AGS-v PLUS was well tolerated and generated a robust immune response in participants, with no serious adverse events. The next steps will be to determine if these findings translate into clinical efficacy against mosquito-borne diseases, which inflict a severe burden on public health systems around the world.”
*This is not investment advice.
Open Orphan (hVIVO) share price.
The HVIVO share price plunged 6.83% to trade at 11.05p, falling from Friday’s closing price of 11.86p.
YOUR CAPITAL IS AT RISK. 76% OF RETAIL CFD ACCOUNTS LOSE MONEY.